Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study

Bibliographic Details
Published in:	Blood Cancer Journal
Main Authors:	Niels W. C. J. van de Donk, Nizar Bahlis, Luciano J. Costa, María-Victoria Mateos, Ajay K. Nooka, Aurore Perrot, Alfred L. Garfall, Pragya Thaman, Keqin Qi, Clarissa Uhlar, Katherine Chastain, Margaret Doyle, Saad Z. Usmani
Format:	Article
Language:	English
Published:	Nature Publishing Group 2024-10-01
Online Access:	https://doi.org/10.1038/s41408-024-01160-1

Similar Items

TECLISTAMAB IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): MAJESTEC-1 SUBGROUP ANALYSIS BY LINES OF THERAPIES
by: NWCJV Donk, et al.
Published: (2023-10-01)

LONG-TERM FOLLOW-UP FROM THE PHASE 1/2 MAJESTEC-1 TRIAL OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS BY LINES OF THERAPIES
by: LJ Costa, et al.
Published: (2024-10-01)

P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY
by: Manisha Bhutani, et al.
Published: (2023-08-01)

P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1
by: J. Martínez-López, et al.
Published: (2022-06-01)

PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: M. V. Mateos, et al.
Published: (2022-06-01)

S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDY
by: Fritz Offner, et al.
Published: (2023-08-01)

P879: LONG-TERM FOLLOW-UP FROM MAJESTEC-1 OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
by: Surbhi Sidana, et al.
Published: (2023-08-01)

P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1
by: R. Popat, et al.
Published: (2022-06-01)

P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: R Popat, et al.
Published: (2022-04-01)

P911: EVALUATION OF PROPHYLACTIC TOCILIZUMAB (TOCI) FOR THE REDUCTION OF CYTOKINE RELEASE SYNDROME (CRS) TO INFORM THE MANAGEMENT OF PATIENTS (PTS) TREATED WITH TECLISTAMAB IN MAJESTEC-1
by: Niels W.C.J. van de Donk, et al.
Published: (2023-08-01)

P32 MAJESTEC-1: CORRELATIVE ANALYSES OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
by: N. van de Donk, et al.
Published: (2023-05-01)

P865: TECLISTAMAB IN COMBINATION WITH LENALIDOMIDE IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA IN THE PHASE 1B MULTICOHORT MAJESTEC-2 STUDY
by: Carlyn Tan, et al.
Published: (2023-08-01)

P30 SINGLE COHORT RESULTS FROM MAJESTEC-2: TECLISTAMAB (TEC) IN COMBINATION WITH SUBCUTANEOUS DARATUMUMAB (DARA) AND LENALIDOMIDE (LEN) IN PATIENTS WITH MULTIPLE MYELOMA (MM)
by: E. Searle, et al.
Published: (2023-05-01)

S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS
by: C. Touzeau, et al.
Published: (2022-06-01)

Teclistamab: Mechanism of action, clinical, and translational science
by: Yue Guo, et al.
Published: (2024-01-01)

P1506: TECLISTAMAB REDUCES POLYCLONAL IMMUNOGLOBULIN LEVELS AND IMPAIRS VACCINATION RESPONSES IN HEAVILY PRETREATED MM PATIENTS
by: Kristine Frerichs, et al.
Published: (2023-08-01)

Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma
by: Amrita Krishnan, et al.
Published: (2023-04-01)

P898: COMPARISON OF TECLISTAMAB WITH BELANTAMAB MAFODOTIN IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA USING MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON
by: M. Delforge, et al.
Published: (2022-06-01)

PB2014: TECLISTAMAB VS SELINEXOR-DEXAMETHASONE IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHING-ADJUSTED INDIRECT COMPARISON
by: L. Rosinol, et al.
Published: (2022-06-01)

PB2013: TECLISTAMAB COMPARED WITH REAL-WORLD THERAPIES IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: A. Krishnan, et al.
Published: (2022-06-01)

Teclistamab therapy for refractory type 1 cryoglobulinemia
by: Justin Battaglini, et al.
Published: (2025-03-01)

Nontuberculous mycobacterial infections following teclistamab in multiple myeloma
by: Matthew Ho, et al.
Published: (2025-02-01)

S190: FIRST RESULTS FROM THE REDIRECTT-1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
by: Maria-Victoria Mateos, et al.
Published: (2023-08-01)

Manifestations of Teclistamab‐Associated Uveitis
by: Gabriel Castilho Barbosa, et al.
Published: (2025-06-01)

P972: INDIRECT COMPARISON OF TECLISTIMAB IN MAJESTEC-1 VERSUS PHYSICIAN’S CHOICE OF THERAPY IN LONG-TERM FOLLOW-UP OF TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN DARATUMUMAB TRIALS
by: K. Weisel, et al.
Published: (2022-06-01)

Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience
by: Sara A. Scott, et al.
Published: (2023-12-01)

S188: TECLISTAMAB IN COMBINATION WITH DARATUMUMAB, A NOVEL, IMMUNOTHERAPY-BASED APPROACH FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS
by: P. Rodriguez Otero, et al.
Published: (2022-06-01)

Legalitas Keberadaan Majelis Pengawas Notaris dan Majelis Kehormatan Notaris
by: Henry Lbn Toruan Donald
Published: (2020-09-01)

B04: COMBINATION OF SUBCUTANEOUS TECLISTAMAB WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1B MULTICOHORT STUDY
by: P Rodriguez-Otero, et al.
Published: (2022-04-01)

P979: PATIENT-REPORTED OUTCOMES FOR TECLISTAMAB VERSUS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY IN THE LOCOMMOTION STUDY IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: Philippe Moreau, et al.
Published: (2023-08-01)

Teclistamab for heavily pretreated relapsed / refractory POEMS syndrome
by: Alexis Talbot, et al.
Published: (2025-07-01)

Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment
by: Danai Dima, et al.
Published: (2025-07-01)

Majeed Amjad: Tradition and Individuality
by: Khizra Tabassum
Published: (2022-12-01)

Majeed Amjad: Wonderer of Earth
by: Ghulam Fareed Hussaini
Published: (2017-12-01)

Majeed Amjad: Tradition and Individuality
by: Khizra Tabassum
Published: (2022-12-01)

Majeed Amjad: Wonderer of Earth
by: Ghulam Fareed Hussaini
Published: (2017-12-01)

Injection site reaction to teclistamab in a patient with multiple myeloma
by: Isabel C. Yoon, BS, et al.
Published: (2025-02-01)

Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis
by: Rajshekhar Chakraborty, et al.
Published: (2023-11-01)

The Salient Stylistic Features of Majeed Amjad
by: Saima Iram, et al.
Published: (2021-12-01)

Imagery and Portrait in Majeed Amjad's Poetry
by: Ejaz Ahmad
Published: (2021-08-01)